EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44hi/CD24lo-ALDH1hi as an Independent Prognostic Factor After Neoadjuvant Chemotherapy

Hazem Ghebeh iD, Jumanah Y Mirza, Taher Al-Tweigeri iD, Monther Al-Alwan iD, Asma Tulbah

International Journal of Molecular Sciences · 2025

DOI: 10.3390/ijms26178219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Hazem Ghebeh und 4 weiteren Autor:innen. Beteiligte Einrichtung: Cell Therapy and Immunobiology Department, King Faisal Specialist Hospital & Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia. Hauptthemen laut MEDLINE: Breast Neoplasms, Neoplastic Stem Cells, CD24 Antigen, Biomarkers, Tumor. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: King Faisal Specialist Hospital & Research Centre, King Faisal Specialist Hospital & Research Centre.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Multiple markers exist for breast cancer stem cells (CSCs), which are believed to represent the phenotypes of various CSC types and/or states. The relationship between each CSC subpopulation/state and the primary hallmarks of cancer has not been sufficiently clarified. In this study, six CSC markers (CD44hi/CD24lo, CD24, Ep-CAM, ALDH1, CD10, and BMI1) were assessed in a surgical cohort of 73 breast cancer patients. The expression of a single or multiple CSC markers was correlated with clinicopathological parameters, including markers of immune evasion, proliferation, epithelial–mesenchymal transition (EMT), and survival. All CSC phenotypes, except for CD10, correlated with markers indicative of higher proliferation. The CD44hi/CD24lo phenotype correlated with markers of EMT and PD-L1 expression, unlike ALDH1hi. Both Ep-CAMhi and CD24hi breast cancer were associated with indicators of immune evasion, including PD-L1 expression, and the infiltration of FOXP3+ and PD-1+ tumor-infiltrating lymphocytes (TIL). While the CD44hi/CD24lo, Ep-CAMhi, and ALDH1hi phenotypes correlated with shorter overall survival (OS), CD24hi correlated with reduced disease-free survival (DFS). Interestingly, among all tested CSC markers, the CD44hi/CD24lo-ALDH1hi combination phenotype correlated with the worst DFS (HR 2.8, p = 0.014 in univariate/multivariate analysis) and OS (p < 0.001, HR 6.4 in univariate and 5.4 in multivariate analysis). A side-by-side comparison of multiple CSC markers demonstrated the differential linkage of CSC phenotype/state with distinct features of breast cancer. This comparison demonstrates the advantage of the CD44hi/CD24lo-ALDH1hi combination marker for prognostication, especially after neoadjuvant chemotherapy. In the future, distinct markers of CSCs can hopefully be leveraged to trace/monitor different disease characteristics or treatment outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsNeoplastic Stem CellsCD24 AntigenBiomarkers, TumorHyaluronan ReceptorsHumansFemaleAldehyde Dehydrogenase 1 FamilyPrognosisMiddle AgedNeoadjuvant TherapyAdultRetinal DehydrogenaseAgedEpithelial-Mesenchymal TransitionIsoenzymes

Stichwörter der Autor:innen

ALDH1BMI1CD10CD24CD44hi/CD24loEp-CAMPD-L1cancer stem cells

Substanzen

Aldehyde Dehydrogenase 1 FamilyCD24 AntigenALDH1A1 protein, humanBiomarkers, TumorHyaluronan ReceptorsRetinal DehydrogenaseCD44 protein, humanCD24 protein, humanIsoenzymes

Autor:innen und Institutionen

  • Cell Therapy and Immunobiology Department, King Faisal Specialist Hospital & Research Centre, P.O. Box 3354, Riyadh 11211, Saudi Arabia.
  • College of Medicine, Al-Faisal University, Riyadh 11533, Saudi Arabia.
  • Oncology Centre, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.
  • Department of Pathology, King Faisal Specialist Hospital & Research Centre, Riyadh 11211, Saudi Arabia.

ORCID-Profile: Hazem Ghebeh, Taher Al-Tweigeri, Monther Al-Alwan

Förderung

  • King Faisal Specialist Hospital & Research Centre
  • King Faisal Specialist Hospital &amp; Research Centre

Zitieren

APA

Ghebeh, H., Mirza, J. Y., Al-Tweigeri, T., Al-Alwan, M., & Tulbah, A. (2025). Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44hi/CD24lo-ALDH1hi as an Independent Prognostic Factor After Neoadjuvant Chemotherapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26178219

Vancouver

Ghebeh H, Mirza JY, Al-Tweigeri T, Al-Alwan M, Tulbah A. Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44hi/CD24lo-ALDH1hi as an Independent Prognostic Factor After Neoadjuvant Chemotherapy. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26178219

BibTeX
@article{Ghebeh2025,
  author = {Ghebeh, Hazem and Mirza, Jumanah Y and Al-Tweigeri, Taher and Al-Alwan, Monther and Tulbah, Asma},
  title = {Profiling of Breast Cancer Stem Cell Types/States Shows the Role of CD44hi/CD24lo-ALDH1hi as an Independent Prognostic Factor After Neoadjuvant Chemotherapy},
  journal = {International Journal of Molecular Sciences},
  year = {2025},
  doi = {10.3390/ijms26178219}
}
Kostenlos starten →